• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

Fluticasone furoate does not improve outpatient COVID-19 outcomes

byNhat Hung (Benjamin) LamandKiera Liblik
October 10, 2023
in Infectious Disease, Public Health, Pulmonology
Reading Time: 2 mins read
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, inhaled fluticasone furoate did not shorten the time to recovery for non-hospitalized patients with mild-to-moderate coronavirus disease 2019 (COVID-19) compared to a placebo. 

2.  Adverse events were not common in the fluticasone furoate or the placebo group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: As the COVID-19 pandemic continues, ongoing efforts are being made to prevent disease transmission and lower the risk of progression to severe disease. Although vaccinations remain the cornerstone of these efforts and effective antiviral agents are now available, there remain accessibility concerns to these therapies in low- and middle-income countries. The systemic glucocorticoid dexamethasone has demonstrated efficacy in treating COVID-19. However, evidence for inhaled glucocorticoids remained inconsistent. This study was a randomized placebo-controlled trial to assess the effectiveness of inhaled fluticasone furoate in treating outpatients with mild-to-moderate COVID-19. Compared to a placebo, treatment with a once-daily dose of inhaled fluticasone furoate did not shorten the time to COVID-19 recovery, nor did it reduce the rates of urgent care or emergency room visits or hospitalization. Both trial groups reported similarly low rates of adverse events. The study was limited by the underrepresentation of persons of color and heterogeneity in placebo formulations (oral or inhaled). These results demonstrated a lack of efficacy of inhaled fluticasone furoate as an outpatient treatment for COVID-19.

Click here to read the study in the NEJM (New England Journal of Medicine)

FDA approvedFor COVID-19: Xocova (ensitrelvir), May 29, 2026→

In-Depth [randomized controlled trial]: The current study was a randomized, double-blind, placebo-controlled trial to investigate the efficacy of inhaled fluticasone furoate in treating outpatients with COVID-19. Adult patients 30 years of age or older who were not hospitalized and had at least two acute infection symptoms for no more than seven days before enrollment were eligible for inclusion. Exclusion criteria included pregnancy, breastfeeding, and recent use of other glucocorticoids. In total, 1,277 participants were randomized 1:1 to receive inhaled fluticasone furoate 200mg once daily or placebo for 14 days. The primary outcome was the time to sustained recovery, defined as reaching three consecutive days without COVID-19 symptoms. Secondary outcomes included a composite of urgent-care or emergency department visits, hospitalizations, or death. No significant difference in time to recovery was observed between the fluticasone furoate and the placebo groups (hazard ratio, 1.01; 95% Credible Interval [CI], 0.91-1.12; posterior probability of benefit, 0.56). There were no deaths, and hospitalizations only occurred in three patients in each group. The composite outcome of urgent-care or emergency department visits or hospitalizations occurred at similar rates in both groups (hazard ratio, 1.9; 95% CI, 0.9-3.5). Subgroup analysis did note that among unvaccinated patients, fluticasone furoate recipients had a longer time to recover, suggesting a variable response to treatment depending on vaccination status. These results demonstrated that inhaled fluticasone furoate did not offer clinical benefits for non-hospitalized patients with mild-to-moderate COVID-19.

RELATED REPORTS

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

Chronic exposure to particulate matter is associated with increased cardiovascular risk

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COVID-19Fluticasone furoateinfectious diseasepublic healthpulmonologyrespirology
Previous Post

Elements of the built environment influence physical activity behaviors in older adults

Next Post

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

RelatedReports

A balance scale weighing an antiviral medication against a hospital entrance and a patient, symbolizing the outcomes of COVID-19 treatment.
2MM Trial Briefs

101-PGC-005 improved hospitalized patients with COVID-19 faster than systemic dexamethasone in topline phase 2/3 results

November 10, 2026
A senior woman looks thoughtfully at a balance scale with a stethoscope and a heart illustration, symbolizing the assessment of cardiovascular risk and treatment decisions.
Cardiology

Chronic exposure to particulate matter is associated with increased cardiovascular risk

September 10, 2026
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Emergency

Lower levels of education and place of birth were associated with non-admission to the intensive care unit in Sweden during COVID-19 pandemic

September 1, 2026
Homelessness and health collage: a park bench with a bedroll and backpack, a path to a building with one lit window
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Next Post

Adjuvant everolimus does not improve survival for patients with resected renal cell carcinoma

Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout

Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares

Ferric carboxymaltose does not improve heart failure with iron deficiency

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
  • Continuation of immunotherapy after immune checkpoint inhibitor-induced myocarditis in patients with lung cancer may be safe and effective
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.